#Canada #Montreal #Thryv Therapeutics #SGK1 inhibitors #THRV-1268

Thryv Therapeutics Unveils Encouraging Phase 1 Results

Thryv Therapeutics Inc., a clinical-stage biotech entity, recently revealed positive outcomes from its Phase 1 clinical trial of THRV-1268, a novel inhibitor targeting serum glucocorticoid inducible kinase 1 (SGK1). This study specifically focused on obese participants, highlighting the drug’s ability to effectively address prolonged QTcF—a significant concern in cardiometabolic diseases.

Conducted with a cohort whose body mass index (BMI) exceeded 30 kg/m², the trial demonstrated a notable reduction in QTcF intervals following a single dose of THRV-1268, indicating its potential to modulate electrical activity in heart function, especially amid escalating obesity rates and related health complications. The findings suggest that THRV-1268 possesses a unique electrophysiologic profile, crucial for developing therapies aimed at obese individuals facing cardiometabolic challenges.

The clinical study focused on evaluating several key parameters including the drug’s pharmacodynamics, pharmacokinetics, safety, and tolerability across two ascending doses. Impressively, THRV-1268 was well tolerated, with no serious adverse effects reported during the trial. The pharmacokinetic results indicated that effective therapeutic levels were maintained throughout the dosing interval, supporting a twice-daily administration schedule. Moreover, a comparative analysis of a new tablet formulation versus the oral suspension showed equivalent pharmacokinetic properties, paving the way for consistent dosage forms in future trials.

Understanding the QTc Duration in Heart Failure

QTc interval length on ECG has emerged as a vital indicator of disease severity and risk of unexpected cardiac events among heart failure patients. In patients experiencing more severe stages of heart failure, research has demonstrated a significantly higher prevalence of QTc prolongation. Approximately half of the patient population with BNP levels exceeding 400 pg/mL show QTc prolongation, which correlates with an increased risk of mortality and sudden cardiac events.

Given this context, Thryv’s approach using SGK1 inhibition through THRV-1268 presents a novel method to tackle both electrical and structural heart changes observed in failure conditions. The potential to mitigate serious cardiovascular risks in heart failure patients through this mechanism offers a promising avenue for treatment.

In light of these findings, Thryv Therapeutics plans to launch the ASPIRE-HF trial in 2026, focused on evaluating THRV-1268 among patients with symptomatic heart failure characterized by reduced ejection fraction (HFrEF) and prolonged QT intervals. This phase 2a study will further elucidate the drug’s efficacy and safety in a more complex patient population more likely to benefit from SGK1 inhibition.

About Thryv Therapeutics

Thryv Therapeutics Inc., based in Montreal, Canada, is at the forefront of developing precise treatment options for genetic channelopathies, cardiometabolic conditions, and cardiomyopathies through selective SGK1 inhibitors. The company is committed to paving new pathways in the treatment of these challenging diseases, potentially changing the landscape of precision medicine. For further details, please visit Thryv Therapeutics.